ClinicalTrials.gg
CompletedNCT01737944Updated Feb 25, 2014Results posted

Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration

A Phase 1/2 interventional study of Methotrexate (MTX) in Rheumatoid Arthritis, sponsored by Antares Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-25.

Sponsored by Antares Pharma Inc. (part of Halozyme Therapeutics) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
95th of 113
38 · median 130
Started
2011
with 6 others
Phase 1/2
Only one
of the 113
Registered
68th of 113
by date

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 95th largest by enrollment, is one of 7 that started in 2011, is the only one in phase 1/2, and was the 68th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Pharmacokinetics (PK) study

Read the detailed description

To compare the pharmacokinetic (PK) profiles of methotrexate (MTX) following a subcutaneous (SC) injection of MTX using the Vibex device to that obtained after an SC injection of MTX without using the device and to that obtained after an intramuscular (IM) injection of MTX in adult subjects with rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • methotrexate injection, subcutaneous, autoinjector
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female >18 years of age with diagnosed Rheumatoid Arthritis(RA).

Exclusion criteria

Exclusion Criteria:

  • Chronic or acute renal disease
  • Any other disease or disorder which, in the opinion of the investigator, might put the subject at risk
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    10mg Methotrexate (MTX) Group

    Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection

    Drug: Methotrexate (MTX)

  • Experimental
    15mg Methotrexate (MTX) Group

    Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection

    Drug: Methotrexate (MTX)

  • Experimental
    20mg Methotrexate (MTX) Group

    Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection

    Drug: Methotrexate (MTX)

  • Experimental
    25mg Methotrexate (MTX) Group

    Treatment Arm A - SC injection with Vibex device, Treatment Arm B - SC injection without device and Treatment Arm C - IM injection

    Drug: Methotrexate (MTX)

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX

    Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment

    Time frame: 24 Hour period

  2. Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX

    Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC\[0-24\]/Dose) for each treatment

    Time frame: 24 Hour period

  3. Bioequivalence Based Upon Dose-Normalized Cmax for MTX

    Dose-normalized maximum observed concentration for each treatment

    Time frame: 24 Hour period

07

Results

Posted Feb 25, 2014

Participant flow

Subjects were screened and enrolled at 2 sites in the US. Approximately equal number of subjects on 10 mg, 15 mg, 20 mg and 25 mg doses were recruited. The dose group was determined by the Investigator based on subject's current therapeutic regimen of MTX and disease status. The patient's dose was the same for the entire study.

Participant flow — Overall Study
Milestone10mg MTX Group15mg MTX Group20mg MTX Group25mg MTX Group
Started9999
Completed9999
Not completed0000

Outcome measures

PrimaryBioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX

Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng*hr/mL/mg
Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX
ng*hr/mL/mgTreatment Arm ATreatment Arm BTreatment Arm C
Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX118.14 ± 42.300122.63 ± 40.648116.71 ± 41.394
Statistical analysis
  • Treatment Arm A vs Treatment Arm B · Test / reference ratio: 96.24 · 90% CI 92.33 to 100.31
  • Treatment Arm A vs Treatment Arm C · Test / reference ratio: 101.28 · 90% CI 97.17 to 105.56
PrimaryBioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX

Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC\[0-24\]/Dose) for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng*hr/mL/mg
Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX
ng*hr/mL/mgTreatment Arm ATreatment Arm BTreatment Arm C
Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX116.60 ± 40.963121.08 ± 39.405122.63 ± 40.648
Statistical analysis
  • Treatment Arm A vs Treatment Arm B · Test / reference ratio: 96.22 · 90% CI 92.32 to 100.28
  • Treatment Arm A vs Treatment Arm C · Test / reference ratio: 101.14 · 90% CI 97.06 to 105.40
PrimaryBioequivalence Based Upon Dose-Normalized Cmax for MTX

Dose-normalized maximum observed concentration for each treatment

Time frame:
24 Hour period
Reported as:
Mean · ng/mL/mg
Bioequivalence Based Upon Dose-Normalized Cmax for MTX
ng/mL/mgTreatment Arm ATreatment Arm BTreatment Arm C
Bioequivalence Based Upon Dose-Normalized Cmax for MTX21.43 ± 8.31022.38 ± 10.26323.37 ± 7.188
Statistical analysis
  • Treatment Arm A vs Treatment Arm B · Test / reference ratio: 96.76 · 90% CI 87.93 to 106.47
  • Treatment Arm A vs Treatment Arm C · Test / reference ratio: 89.79 · 90% CI 81.61 to 98.78

Adverse events

Collected over The Safety Population was defined as all randomized subjects who received at least 1 dose of study drug. The Safety Population included 36 subjects.. Non-serious events are listed at a 2.8% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10mg MTX—0/9 (0%)1/9 (11.1%)
15mg MTX—0/9 (0%)0/9 (0%)
20mg MTX—0/9 (0%)2/9 (22.2%)
25mg MTX—0/9 (0%)1/9 (11.1%)
Most frequent other events
Most frequent other events
Event10mg MTX15mg MTX20mg MTX25mg MTX
Maculopapular rashSkin and subcutaneous tissue disorders1/90/90/90/9
NasopharyngitisInfections and infestations0/90/91/90/9
HypertensionVascular disorders0/90/90/91/9
Injection site erythemaGeneral disorders0/90/91/90/9

Baseline characteristics

38 subjects were randomized to a treatment sequence. Two subjects discontinued prior to receiving the first study drug dose. Safety Population = 36 subjects who received study drug and completed all study visits. All 36 subjects were included in Pharmacokinetic Population. No discontinuations after first study drug dose.

Age, Categorical
Age, Categorical(Participants)10mg MTX Group15mg MTX Group20mg MTX Group25mg MTX GroupTotal
<=18 years00000
Between 18 and 65 years767727
>=65 years23229
Age, Continuous
Age, Continuous(years)10mg MTX Group15mg MTX Group20mg MTX Group25mg MTX GroupTotal
Mean61.2 ± 10.9763.4 ± 7.2660.8 ± 6.1863.0 ± 6.8062.1 ± 7.76
Sex: Female, Male
Sex: Female, Male(Participants)10mg MTX Group15mg MTX Group20mg MTX Group25mg MTX GroupTotal
Female756725
Male243211
Region of Enrollment
Region of Enrollment(participants)10mg MTX Group15mg MTX Group20mg MTX Group25mg MTX GroupTotal
United States999936
08

Study locations

1 site
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2014, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2012
First posted
Nov 30, 2012
Start
Jan 2011
Primary completionActual
May 2011
CompletionActual
Jun 2011
Results first posted
Feb 25, 2014
Last update
Feb 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01737944
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Jan 2011
Primary completion
May 2011
Completion
Jun 2011
Results posted
Feb 25, 2014
Last update
Feb 25, 2014

Study contacts

Alan J Kivitz, MD;CPI
principal investigator · Altoona Center for Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion